These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 34504204)

  • 1. Role of CXCL10 in the progression of in situ to invasive carcinoma of the breast.
    Kim M; Choi HY; Woo JW; Chung YR; Park SY
    Sci Rep; 2021 Sep; 11(1):18007. PubMed ID: 34504204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The prognostic significance of immune microenvironment in breast ductal carcinoma in situ.
    Toss MS; Abidi A; Lesche D; Joseph C; Mahale S; Saunders H; Kader T; Miligy IM; Green AR; Gorringe KL; Rakha EA
    Br J Cancer; 2020 May; 122(10):1496-1506. PubMed ID: 32203210
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune Escape in Breast Cancer During
    Gil Del Alcazar CR; Huh SJ; Ekram MB; Trinh A; Liu LL; Beca F; Zi X; Kwak M; Bergholtz H; Su Y; Ding L; Russnes HG; Richardson AL; Babski K; Min Hui Kim E; McDonnell CH; Wagner J; Rowberry R; Freeman GJ; Dillon D; Sorlie T; Coussens LM; Garber JE; Fan R; Bobolis K; Allred DC; Jeong J; Park SY; Michor F; Polyak K
    Cancer Discov; 2017 Oct; 7(10):1098-1115. PubMed ID: 28652380
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Functional CD3
    Lv S; Wang S; Qiao G; Wang X; Zhou X; Yan F; Li Y; Wang S; Morse MA; Hobeika A; Ren J; Lyerly HK
    Clin Breast Cancer; 2019 Oct; 19(5):e617-e623. PubMed ID: 31101455
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic role of immune infiltrates in breast ductal carcinoma in situ.
    Chen XY; Yeong J; Thike AA; Bay BH; Tan PH
    Breast Cancer Res Treat; 2019 Aug; 177(1):17-27. PubMed ID: 31134489
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The immune microenvironment of breast ductal carcinoma in situ.
    Thompson E; Taube JM; Elwood H; Sharma R; Meeker A; Warzecha HN; Argani P; Cimino-Mathews A; Emens LA
    Mod Pathol; 2016 Mar; 29(3):249-58. PubMed ID: 26769139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Relationship of the Breast Ductal Carcinoma
    Hendry S; Pang JB; Byrne DJ; Lakhani SR; Cummings MC; Campbell IG; Mann GB; Gorringe KL; Fox SB
    Clin Cancer Res; 2017 Sep; 23(17):5210-5217. PubMed ID: 28611201
    [No Abstract]   [Full Text] [Related]  

  • 9. Ductal carcinoma in situ of the breast: immune cell composition according to subtype.
    Agahozo MC; van Bockstal MR; Groenendijk FH; van den Bosch TPP; Westenend PJ; van Deurzen CHM
    Mod Pathol; 2020 Feb; 33(2):196-205. PubMed ID: 31375764
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Higher densities of tumour-infiltrating lymphocytes and CD4
    Thike AA; Chen X; Koh VCY; Binte Md Nasir ND; Yeong JPS; Bay BH; Tan PH
    Histopathology; 2020 May; 76(6):852-864. PubMed ID: 31883279
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Expression profiling of in vivo ductal carcinoma in situ progression models identified B cell lymphoma-9 as a molecular driver of breast cancer invasion.
    Elsarraj HS; Hong Y; Valdez KE; Michaels W; Hook M; Smith WP; Chien J; Herschkowitz JI; Troester MA; Beck M; Inciardi M; Gatewood J; May L; Cusick T; McGinness M; Ricci L; Fan F; Tawfik O; Marks JR; Knapp JR; Yeh HW; Thomas P; Carrasco DR; Fields TA; Godwin AK; Behbod F
    Breast Cancer Res; 2015 Sep; 17():128. PubMed ID: 26384318
    [TBL] [Abstract][Full Text] [Related]  

  • 12. FOXP3-positive regulatory T lymphocytes and epithelial FOXP3 expression in synchronous normal, ductal carcinoma in situ, and invasive cancer of the breast.
    Lal A; Chan L; Devries S; Chin K; Scott GK; Benz CC; Chen YY; Waldman FM; Hwang ES
    Breast Cancer Res Treat; 2013 Jun; 139(2):381-90. PubMed ID: 23712790
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Tumor-Infiltrating Lymphocytes in a Contemporary Cohort of Women with Ductal Carcinoma In Situ (DCIS).
    Darvishian F; Ozerdem U; Adams S; Chun J; Pirraglia E; Kaplowitz E; Guth A; Axelrod D; Shapiro R; Price A; Troxel A; Schnabel F; Roses D
    Ann Surg Oncol; 2019 Oct; 26(10):3337-3343. PubMed ID: 31240590
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Analysis of tumour-infiltrating lymphocytes reveals two new biologically different subgroups of breast ductal carcinoma in situ.
    Beguinot M; Dauplat MM; Kwiatkowski F; Lebouedec G; Tixier L; Pomel C; Penault-Llorca F; Radosevic-Robin N
    BMC Cancer; 2018 Feb; 18(1):129. PubMed ID: 29394917
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The transcriptional regulator TBX3 promotes progression from non-invasive to invasive breast cancer.
    Krstic M; Macmillan CD; Leong HS; Clifford AG; Souter LH; Dales DW; Postenka CO; Chambers AF; Tuck AB
    BMC Cancer; 2016 Aug; 16(1):671. PubMed ID: 27553211
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis.
    Bi X; Hameed M; Mirani N; Pimenta EM; Anari J; Barnes BJ
    Breast Cancer Res; 2011; 13(6):R111. PubMed ID: 22053985
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tumoral lymphocytic infiltration and expression of the chemokine CXCL10 in breast cancers from the Ontario Familial Breast Cancer Registry.
    Mulligan AM; Raitman I; Feeley L; Pinnaduwage D; Nguyen LT; O'Malley FP; Ohashi PS; Andrulis IL
    Clin Cancer Res; 2013 Jan; 19(2):336-46. PubMed ID: 23213058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ras-induced modulation of CXCL10 and its receptor splice variant CXCR3-B in MDA-MB-435 and MCF-7 cells: relevance for the development of human breast cancer.
    Datta D; Flaxenburg JA; Laxmanan S; Geehan C; Grimm M; Waaga-Gasser AM; Briscoe DM; Pal S
    Cancer Res; 2006 Oct; 66(19):9509-18. PubMed ID: 17018607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of immune checkpoint regulators, cytotoxic T lymphocyte antigen 4 (CTLA-4) and programmed death-ligand 1 (PD-L1), in female breast carcinomas.
    Kassardjian A; Shintaku PI; Moatamed NA
    PLoS One; 2018; 13(4):e0195958. PubMed ID: 29672601
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence that molecular changes in cells occur before morphological alterations during the progression of breast ductal carcinoma.
    Castro NP; Osório CA; Torres C; Bastos EP; Mourão-Neto M; Soares FA; Brentani HP; Carraro DM
    Breast Cancer Res; 2008; 10(5):R87. PubMed ID: 18928525
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.